Iridex 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- IRIDEX reported 3rd quarter 2026 revenue of $10.2 million, compared to $12.5 million in the 3rd quarter of 2025; the decline was driven primarily by international retina and lower international probe orders, partially offset by growth in U.S. glaucoma.
- Retina product revenue was $5.1 million, compared to $6.7 million in the prior year quarter, while Cyclo G6 product family revenue was $3.2 million, compared to $3.5 million.
- Gross profit was $4.3 million and gross margin was 42.4%, compared to $4.0 million and 32.1% in the prior year quarter; excluding the one-time $0.8 million inventory write-down in the 3rd quarter of 2025, prior-year gross margin was 38.7%.
- Operating expenses were $5.5 million, compared to $5.4 million; net loss was $1.4 million, or $0.08 per share, compared to a net loss of $1.6 million, or $0.09 per share.
- Non-GAAP adjusted EBITDA was a loss of $0.6 million, compared to a loss of $0.1 million in the 3rd quarter of 2025.
- Cash and cash equivalents were $3.7 million as of October 3rd, 2026, compared to $4.7 million at the end of the 2nd quarter; net cash used in operating activities was $1.0 million, including a $1.6 million increase in inventory.
- U.S. G6 probe volume was 6,900 units, roughly in line with the prior year period, and 8 G6 systems were placed in the U.S., compared to 7; global G6 probe volume was approximately 11,900 units, compared to 14,900.
- U.S. Pascal revenue increased approximately 50% year over year.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Ladies and gentlemen, thank you for standing by. My name is Abby, and I will be your conference operator today. At this time, I would like to welcome everyone to the IRIDEX Third Quarter 2026 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question during that time, simply press star followed by the number 1 on your telephone keypad. If you would like to withdraw your question, press star one again. Thank you. I would now like to turn the conference over to Trip Taylor, Investor Relations.
You may begin. Thanks, operator, and good afternoon, everyone.
Joining me on the call today from IRIDEX are Patrick Mercer, Chief Executive Officer, and Romeo Dizon, Chief Financial Officer. After the market closed today, IRIDEX released its financial results for the third quarter ended October 3rd, 2026. The release is available in the Investor Relations section of the company's website. Please note that today's discussion contains forward-looking statements within the meaning of the federal securities laws made under safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are any statements that do not relate strictly to historical facts, including statements about our strategy, goals, and priorities, our financial outlook, product development and regulatory matters, sales trends, and the markets we serve.
These statements reflect management's current expectations and assumptions and are subject to significant risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied today. You should not place undue reliance on them. A discussion of these risks can be found in our most recent annual report on Form 10-K and quarterly reports on Form 10-Q on file with the SEC. Except as required by law, IRIDEX undertakes no obligation to update or revise any forward-looking statements or financial projections, whether as a result of new information, future developments, or otherwise. During the call, we will also reference certain non-GAAP measures, including adjusted EBITDA and adjusted operating expenses. A reconciliation to the most directly comparable GAAP measure is included in today's press release. This call includes time-sensitive information that is accurate only as of the date of this live broadcast, November 17th, 2026.
With that, I'll turn the call over to Patrick.
Thank you, Tripp. Good afternoon, everyone, and thanks for being with us today. The recently completed quarter included some of the most important structural progress we have made recently as a company. Key among the many recent developments was the completion of our manufacturing relocation to our new headquarters in San Jose. Also noteworthy during the quarter was the significant improvement in gross margins, increasing 10 percentage points year-over-year and 8 percentage points sequentially. During the third quarter of 2025, we recorded a one-time write-off of approximately $0.8 million to cost of goods sold. Excluding this impact, pro forma gross margin was 38.7%, representing a solid 370 basis point improvement. Together, these examples underscore the meaningful progress underway as we continue to retool and reposition our business, executing on our commitment to achieving sustainable profitability.
While we continue to make meaningful progress on our longer-term strategic initiatives and operational improvements, we did encounter some headwinds in the third quarter, with revenue coming in below expectations. This was primarily driven by the timing of international retina orders, international distributors working through probe inventory accumulated in anticipation of our manufacturing relocation, and ongoing regulatory delays. The third quarter results were disappointing, particularly given that they diverged from the positive trends we had observed earlier in the quarter. Regardless of the contributing factors, our results fell short of expectations, and we have already begun taking decisive steps to address these headwinds. Our focus is clear. Every significant decision we make during the remainder of 2026 will be guided by a single objective: positioning IRIDEX to achieve greater profitability in 2027. I'll spend part of today outlining the actions we are taking and what the path forward looks like.
In reviewing our forward-looking plans, let's start with operations. On October 5th, we finished moving our manufacturing operations from Mountain View to newer, more efficient, and significantly less expensive space in nearby San Jose. The relocation was a complex project, and our team executed it while keeping our quality systems intact. Since completing the move, we have successfully completed both our TÜV and BSI audits, and we are now waiting on the final audit reports and certificates to initiate manufacturing for international markets at our new location. We anticipate this relocation should deliver approximately $600,000 in annualized rent savings with additional opportunities for manufacturing benefits expected as the new site is fully integrated into day-to-day operations. The new location gives us a facility that is right-sized for the business we intend to run.
As we outlined on our last call, a change in our manufacturing address requires re-registration in a number of international markets, and this creates short windows where we cannot ship under the new registration. To protect our distributors and their customers during those windows, we built safety stock utilizing the old address. That increased inventory is now starting to convert to revenue as international regulatory clearances are completed, and we continue to receive orders tied to upcoming blackout periods. This will become a tailwind for cash flows as working capital and inventory is steadily converted back into cash. The combination of our inventory investment and the lower-than-expected third quarter revenue resulted in a cash use of roughly $1 million in the quarter. As safety stock converts to revenue and we collect the related receivables, we are driving towards a return to cash flow breakeven.
Glaucoma developments continue to be very encouraging. In the U.S., G6 product family revenue grew, supported by higher average selling prices and an increase in system places. Internationally, probe orders were lower in the quarter as distributors worked through inventory they purchased in the first half, a pattern we flagged the last quarter. In retina, U.S. PASCAL sales were the highlight of the segment, with year-over-year sales increasing by approximately 50%. The rest of the retina business was challenged as a mix of deferred orders, regulatory constraints, and competitive pricing in specific international markets impacted sales. I will now discuss each segment in further detail, starting with glaucoma. We saw several bright spots in U.S. glaucoma performance throughout the quarter, driven by the same three factors we highlighted last quarter: Medicare LCD tailwinds, targeted outreach through MedScout, and higher average selling prices.
First, the Medicare LCD changes continue to improve the reimbursement environment and are encouraging physicians to consider MicroPulse TLT with G6 earlier in the treatment pathway. Our two-year clinical follow-up data on MicroPulse TLT reinforces that shift. Longer-term outcome data gives us a strong foundation for physician education and supports earlier use of the therapy, including in selected patients with mild to moderate disease. Second, our utilization platform continues to sharpen our commercial focus. MedScout helps our team target mid-utilization accounts and high-volume MIGS surgeons, where we see the clearest path to greater adoption. We also left the American Academy of Ophthalmology conference with strong physician interest and active commercial conversations, which we expect to support adoption and utilization in the months ahead. Third, pricing remains a meaningful contributor. U.S. G6 probe ASP increased in 2025, and we have held that higher price level consistently throughout 2026.
We believe this reflects the value physicians place on MicroPulse therapy. G6 probe volume in the U.S. was 6,900 units, roughly in line with the prior year period, and we placed eight G6 systems in the U.S. compared to seven in the prior year quarter. Global G6 probe volume was approximately 11,900 units versus 14,900 in the prior year, with the declines coming primarily from international distributor ordering patterns. On systems, we placed 28 G6 systems in the quarter compared to 30 in the third quarter of 2025. Going deeper into details impacting our international glaucoma business, in Europe, Middle East, and Africa, results were shaped mainly by order timing. Distributors accelerated G6 console and probe orders in the first and second quarters, which reduced third quarter demand, and tighter inventory and purchasing controls at one of our larger distribution partners added to the effect.
Supply constraints also delayed fulfillment of some G6 Probe Illuminate orders. In Germany and Austria, they continue to perform above plan as we recover business previously handled by our former distributor. New G6 console placements remain competitive, particularly against the ART BOX platform. In Asia, continued economic challenges in China contributed to relatively stagnant order activity in the third quarter. In Japan, customers had placed significant orders in the second quarter ahead of our headquarters relocation and the associated business transition, resulting in lighter third quarter purchasing as anticipated. Stocking orders in Korea and Malaysia ahead of the address change helped partially offset softer demand elsewhere in the region. Importantly, all outstanding EndoProbe backorders carried over from the second quarter for customers in China and Japan have now been fulfilled. In Latin America and Canada, G6 probe sales were stable.
Orders from Peru and Chile offset lower purchasing in Brazil, where our distributor built inventory in the second quarter. Canada continues to deliver steady results following the commercial changes we made earlier this year. Overall, the drivers of our glaucoma business remain intact: favorable reimbursement, a growing body of clinical evidence, more focused selling, and disciplined pricing. We remain focused on turning those advantages into steady probe volume growth and additional system places. Now turning to retina. Our retina strategy continues to rest on three priorities: advancing the PASCAL upgrade cycle in the U.S., expanding PASCAL's international reach, and securing regulatory clearances for our next-generation platforms. We saw several bright spots domestically this quarter. U.S. PASCAL revenue increased approximately 50% year over year. Internationally, retina faced challenges concentrated in Asia and Europe. Turning first to Asia. In Japan, our partner deferred PASCAL shipments into the fourth quarter after building inventory ahead of our manufacturing relocation.
This deferral included one particular order of approximately $300,000 that we expect to ship in the fourth quarter. In China, economic weakness, regulatory challenges, and slow tender cycles continue to limit activity. In India, registration delays continue to limit our business to PASCAL sales only. In Europe, Middle East, and Africa, medical retina faced aggressive pricing pressure from larger competitors across Europe. Delays in PASCAL MDR certification also continue to restrict sales in key markets, including Germany and Austria. We continue to expect PASCAL MDR approval in the first half of 2027 and anticipate solid demand once completed. In Latin America and Canada, PASCAL sales have resumed after early market disruption, and we expect further improvement through year-end.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
5 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
